机构：[1]Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China[2]Zhengzhou Univ, Dept Canc, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China[3]First Affiliated Hosp Xinxiang Med, Xinjiang, Henan, Peoples R China[4]Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China[5]Chifeng Municipal Hosp, Dept Med Oncol, Chifeng, Peoples R China[6]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院[7]Hebei Prov Tumor Hosp, Sijiazhuang, Peoples R China河北医科大学第四医院[8]Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China河南省肿瘤医院[9]Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China[10]Canc Hosp, Beijing, Peoples R China
Huang Jing,Fan Qingxia,Lu Ping,et al.A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification[J].JOURNAL OF CLINICAL ONCOLOGY.2015,33(15):doi:10.1200/jco.2015.33.15_suppl.4044.
APA：
Huang, Jing,Fan, Qingxia,Lu, Ping,Ying, Jianming,Ma, Changwu...&Sun, Yan.(2015).A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification.JOURNAL OF CLINICAL ONCOLOGY,33,(15)
MLA：
Huang, Jing,et al."A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification".JOURNAL OF CLINICAL ONCOLOGY 33..15(2015)
医学